论文部分内容阅读
目的：探讨卡维地洛对慢性充血性心力衰竭( CHF)患者血清基质金属蛋白酶-2、9、10水平的影响及其疗效。方法：76例CHF患者随机分为观察组与对照组。两组患者均予以强心(地高辛)、利尿(噻嗪类)和扩张血管(硝酸酯类)等常规治疗。观察组在此基础上加用卡维地洛片治疗，连用6个月。观察两组患者治疗前和治疗6个月后患者血清MMP-2、9、10水平变化，并进行疗效及安全性观察。结果：治疗6个月后，两组血清MMP-2、9、10水平均有明显下降(P<0.05)，且观察组各指标较对照组下降更显著(P<0.05)；同时观察组总有效率为94.74%，明显高于对照组的78.75%(P<0.05)。结论：卡维地洛治疗CHF具有良好的疗效和安全性，作用机制可能与降低血清MMP-2、9、10水平密切相关。“,”Objective: To study the influence and curative effect of carvedilol on serum matrix metalloproteinase -2, 9 and 10 (MMP-2, 9 and 10) in the patients with chronic congestive heart failure (CHF). Methods:Totally 76 patients with CHF were select-ed and randomly divided into the observation group and the control group. All the patients were given routine medical treatment, inclu-ding cardiotonic treatment ( digoxin) , diuresis ( thiadiazide) , vascular dilation ( nitrate ester) and so on. The patients in the observa-tion group were additionally given carvedilol for 6 months. The changes of serum MMP-2, 9 and 10 levels in the patients before the treatment and 6 months after the medical treatment were observed, and the curative effect and safety were studied as well. Results:Af-ter the 6-month medical treatment, the serum MMP-2, 9 and 10 levels in all the patients were obviously declined(P<0. 05), and the declining rates in the observation group were much higher than those in the control group(P<0. 05). Meanwhile, the total clinical effi-ciency of the observation group was 94. 74%, which was higher than that of the control group (78. 95%) (P<0. 05). Conclusion:Carvedilol has favorable curative effect and safety in the treatment of CIF, and the underlying mechanism may be relative to the de-crease of serum MMP-2, 9 and 10 levels.